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Purpose: Childhood obesity is associated with nonalcoholic fatty liver disease (NAFLD), and it has 
become one of the most common causes of childhood chronic liver diseases which significant as a 
cause of liver related mortality and morbidity in children in the United States. The development of 
simpler and easier clinical indices for medical practice is needed to identify advanced hepatic fibrosis 
in childhood NAFLD instead of invasive method like liver biopsy. FibroScan and aspartate amino­
transferase (AST)­to­platelet ratio index (APRI) have been proposed as a simple and noninvasive 
predictor to evaluate hepatic fibrosis in several liver diseases. APRI could be a good alternative to 
detect pathologic change in childhood NAFLD. The purpose of this study is to validate the efficacy of 
APRI for assessing hepatic fibrosis in childhood NAFLD based on FibroScan. 
Methods: This study included 23 children with NAFLD who underwent FibroScan. Clinical, laboratory 
and radiological evaluation including APRI was performed. To confirm the result of this study, 6 patients 
received liver biopsy. 
Results: Factors associated with hepatic fibrosis (stiffness measurement >5.9 kPa Fibroscan) were 
triglyceride, AST, alanine aminotransferase, platelet count, APRI and collagen IV. In multivariate 
analysis, APRI were correlated with hepatic fibrosis (>5.9 kPa). In receiver operating characteristics 
curve, APRI of meaningful fibrosis (cutoff value, 0.4669; area under the receiver operating charac­
teristics, 0.875) presented sensitivity of 94%, specificity of 66%, positive predictive value of 94%, and 
negative predictive value of 64%. 
Conclusion: APRI might be a noninvasive, simple, and readily available method for medical practice to 
predict hepatic fibrosis of childhood NAFLD.
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Introduction
The world wide increase in childhood obesity is a significant problem. Obesity is 
associated with nonalcoholic fatty liver disease (NAFLD), which has become one of 
the most common causes of childhood chronic liver diseases in the United States
1). 
NAFLD represents a group of diseases ranging from asymptomatic simple fatty liver 
to nonalcoholic steatohepatitis (NASH) characterized by the histological evidence http://dx.doi.org/10.3345/kjp.2013.56.1.19
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of apoptosis/inflammation/fibrosis, and to cryptogenic 
cirrhosis
2). NAFLD is also important as a cause of liver-related 
mor  tality and morbidity. Therefore, early identification of 
fibrosis in children is crucial
3). Currently, liver biopsy is the gold 
standard assessment method to investigate hepatic fibrosis and 
inflammation. However, due to the inva  siveness of liver bio-
psy, it may not be recom mended for use in children. Also, it is 
challenging to use liver biopsy as a reoperation for therapeutic 
and follow-up purposes
4,5). Therefore, an accurate noninvasive 
procedure to detect the degree of hepatic fibrosis in NAFLD 
is needed. A noninvasive, rapid, painless, and reproducible 
technique, transient elasto  graphy (FibroScan, Echosens, Paris, 
France) has been develop  ed to measure liver stiffness
6). Liver 
stiff  ness and the severity of liver fibrosis in patients with 
NAFLD have a significant and positive correla  tion with the 
results of liver biopsies. Thus, FibroScan can be a useful and 
objective method to assess the degree of liver fibrosis in NAFLD 
patients
7). How ever, the high cost of FibroScan equipment and 
the need of skillful specialists limit its broad use, especially in 
medical practices
8). For this reason, the development of simpler 
and easier clinical and laboratory indices for medical practice 
are needed to identify advanced fibrosis in patients with 
NALFD. The aspartate amino  transferase (AST)-to-platelet ratio 
index (APRI) has been proposed as a simple and noninvasive 
predictor to evaluate hepatic fibrosis in several liver diseases
9). 
The assess  ment predictors of biological liver function include 
simple blood parameters such as AST and platelets are easy to 
use and esti  mate. Therefore, APRI could be a good alternative 
diagnostic method to FibroScan or liver biopsy
8). The purpose 
of this study is to validate the efficacy of APRI for assessing 
hepatic fibrosis in childhood NASH based on FibroScan.
Materials and methods
1. Patients
We evaluated the clinical and laboratory data of 23 pediatric 
NASH patients (male/female, 22/1) who underwent FibroScan 
at Severance Children’s Hospital in Seoul, Korea, between 
March 2008 and February 2011. The diagnosis of NASH 
was based on: 1) laboratory, radiological, or histopathologic 
characteristics of steatohepatitis, 2) no history of alcohol 
consumption, and 3) no other underline liver diseases
10).
2. Clinical, laboratory and radiological evaluation
Weight, height, and body mass index were calculated. 
Blood test results were obtained after overnight fasting for 
measurement of serum AST, alanine aminotransferase (ALT), 
albumin, total bilirubin, platelet count, prothrombin time 
international nor    malized ratio, cholesterol, triglyceride (TG), 
glucose, col  lagen IV, hyaluronic acid, and AST/ALT ratio 
(AAR). Ultras  onography (US) and fat magnetic resonance 
imaging (MRI) quantification of the liver were performed.
3. APRI
APRI=[(AST/upper limit of normal)/platelet count (10
9/L)]× 
100
11)
4. Liver stiffness measurement (LSM, FibroScan)
The technical instructions of Fibroscan (Ecosens, Paris, 
France) have been described in detail in our previous reports
12). 
Briefly, an ultrasound transducer probe with an external 
diameter of 9 mm is mounted on the axis of a vibrator. 
Vibrations of low amplitude and low frequency (50 Hz) are 
transmitted by the transducer, which induce an elastic shear 
wave that propagates through the underlying tissues. Pulse-
echo ultrasound acqui  sition is used to follow the propagation 
of the shear wave and to measure its velocity, which is directly 
related to tissue stiffness (the elastic modulus E expressed as 
E=3ρV
2, where V is the shear velocity and ρ is the mass density 
[constant for tissues]): the stiffer the tissue, the faster the shear 
wave propagates
13). Transient elastography measures liver stiff-
ness between 25 mm and 65 mm below the skin surface in a 
volume that ap proxi  mates a cylinder that is 1 cm wide and 4 
cm long. This volume is at least 100 times larger than a biopsy 
sample and is, therefore, far more representative of the hepatic 
parenchyma
14). We measured the liver stiffness of the children 
in our study as reported previously
6). In brief, liver stiffness 
was measured quantitatively on the right lobe of liver through 
the intercostal spaces with the child in the supine position 
with maximal abduction of the right arm until 10 successful 
measurements were obtained. The median value of the 10 mea-
surements of liver stiffness was calculated automatically by 
software on a microcomputer installed in the FibroScan. The 
score was expressed as the liver stiffness score in kilopascals 
(kPa). A success rate for measurement of at least 60% has been 
considered reliable
14,15). However, in our study, patients with a 
success rate less than 90% were excluded from the analyses in 
an effort to make the data even more reliable
6,16).
5. Liver biopsy
Liver biopsy with core biopsy gadget (18-G needle, 150 mm 
length; Biopince, Amedic, Sollentuna, Sweden) was conducted 
to obtain liver tissues by our previous study
12). Specimens con-
taining at least 10 portal tracts and of at least 15 mm length 
were used and studied by a pathologist. Biopsy specimens were 
fixed in formalin and embedded in paraffin. Four-micrometer-
thick sections were stained with hematoxylin-eosin-safran, 
Masson trichrome, and Victoria blue. All specimens were an-
alyzed twice by an experienced liver pathologist blinded to 21 http://dx.doi.org/10.3345/kjp.2013.56.1.19
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the clinical data. Following the methods of Nobili et al.
5), the 
main histological features commonly described in NALFD/
NASH (steatosis, inflammation [portal and lobular], hepatocyte 
ballooning, and fibrosis) were scored according to the Scoring 
System for NAFLD recently developed by the National Institutes 
of Health-sponsored NASH Clinical Research Network and 
mean NAFLD activity score (NAS) was calculated. The degree 
of fibrosis was quantified on a 4-point scale: 0, absence of 
fibrosis; 1, perisinusoidal or portal fibrosis; 2, perisinusoidal 
and portal/periportal fibrosis; 3, septal or bridging fibrosis; 4, 
cirrhosis. Liver biopsy was performed in 6 patients.
6. Ethical clearance
This study was approved by the Institutional Review Board 
of Yonsei University College of Medicine, Severance Hospital 
and carried out in accordance with the Helsinki Declaration 
(as revised in Edinburgh, 2000). Informed written consent was 
ob  tained from all patients or appropriate surrogates prior to 
study enrollment.
7. Statistical analysis
Analysis of the data was performed with PASW ver. 18.0 
(IBM Co., Armonk, NY, USA). Univariate analysis was con-
ducted to evaluate the significance of group differences. 
Logistic regression models were performed for multivariate 
analysis to identify the most significant correlation among 
the variables. All variables in univariate analyses with P<0.05 
were introduced into the multivariate analysis. The diagnostic 
performance of the APRI was assessed using receiver opera-
ting characteristics (ROC) curves. All cutoff values are asso-
ciated with the probability of a true positive (sensitivity) 
and a true negative (specificity). The ROC curve is a plot of 
sensitivity versus 1-specificity for all possible cutoff values. 
The most commonly used accuracy index is the area under the 
ROC curve; values near 1.0 indicate high diagnostic accuracy. 
ROC curves were constructed for determination of hepatic 
fibrosis in patient with NAFLD
17). Using ROC curves, the 
optimal cutoff value for APRI was chosen to show a 95% sensi-
tivity, or to obtain a 95% specificity. Furthermore, to optimize 
the diagnostic performance, the sum of true positives and true 
negatives over the total number of patients were calculated to 
Table 1. Univariate analysis for factors associated with hepatic fibrosis in childhood nonalcoholic steatohepatitis
Characteristic Total 
(n=23)
Fibrosis
(stiffness>5.9 kPa) (n=16)
Nonfibrosis
(stiffness≤5.9 kPa) (n=7) P value
Age (yr) 12.7±2.4 12.9±2.2 12.1±3.0 0.521
Male 22 (96) 15 (94) 7 (100) 0.696
Height (cm) 159.8±12.7 161.4±13.0 156.1±12.2 0.371
Weight (kg) 70.2±15.5 72.8±14.9 64.3±16.1 0.233
Body mass index (kg/m
2) 27.3±3.32 27.5±2.84 26.7±4.46 0.079
Cholesterol (mg/dL) 179.7±27.7 180.6±28.9 177.7±26.9 0.827
Triglyceride (mg/dL) 136.8±60.6 157.3±56.6 85.5±35.9 0.011
FBS (mg/dL) 93.2±10.5 94.2±12.6 91.0±3.1 0.521
AST (IU/L) 80.9±69.2 98.8±76.5 40.0±10.8 0.049
ALT (IU/L) 134.4±105.4 159.5±116.2 76.9±37.3 0.033
Albumin (g/dL) 4.7±0.3 4.7±0.3 4.6±0.2 0.572
T. bil (mg/dL) 0.5±0.1 0.5±0.1 0.5±0.2 0.851
Platelet count (10
3/μL) 312.0±62.5 290.1±47.0 362.0±67.9 0.008
PT­INR 0.96±0.04 0.96±0.03 0.98±0.06 0.281
AAR 0.56±0.15 0.56±0.13 0.56±0.19 0.972
APRI 0.82±0.77 1.04±0.83 0.33±0.08 0.015
Hyaluronic acid (ng/dL) 15.8±5.0 15.4±6.1 16.8±3.2 0.582
Collagen IV (ng/dL) 165.0±67.9 190.0±56.2 90.0±36.4 0.045
fatMRI dual echo (%) 34.05±9.48 32.87±9.30 36.24±10.16 0.463
fatMRI triple echo (%) 22.76±7.80 21.52±7.02 25.07±9.21 0.345
Liver stiffness (kPa) 7.45±2.89 8.44±2.95 5.12±0.59 0.009
FibroScan success rate (%) 99.1±1.9 98.8±2.2 100±0  
Values are presented as mean±standard deviation or number (%).
FBS, fasting blood sugar; AST, aspartate aminotransferase; ALT, alanine aminotransferase; T. bil, total bilirubin; PT­INR, prothrombin time­international normalized 
ratio; AAR, AST/ALT ratio; APRI, AST to platelet ratio index; MRI, magnetic resonance imaging.http://dx.doi.org/10.3345/kjp.2013.56.1.19
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maximize the sum of sensitivity and specificity. 
Results
1. Factors associated with hepatic fibrosis
A total of 23 childhood NAFLD patients were included in 
the investigation. The clinical characteristics of all patients 
are pre  sented in Table 1. Based on recent studies
7), the optimal 
cutoff value of hepatic fibrosis was set as 5.9 kPa. Sixteen 
people were in the fibrosis group with liver stiffness greater 
than 5.9 kPa and 7 people were in the nonfibrosis group with 
stiffness lesser than 5.9 kPa. There was no gender difference 
in liver stiffness values. TG, AST, ALT, platelet count, APRI, 
and collagen IV had significant statistical differences. A 
multivariate analysis was done using the variable given by 
the univariate analysis. AST and APRI were correlated with 
hepatic fibrosis (stiffness greater than 5.9 kPa). TG, ALT, 
platelet count, and collagen IV had no relationship with he-
patic fibrosis (Table 2).
2. Accuracy of APRI
Fig. 1 shows a ROC curve line represented by APRI values 
of hepatic flexibility and diagnostic accuracy about hepatic 
fibrosis and cirrhosis. The areas under ROC value according 
to APRI was 0.875, which show high diagnostic accuracy in 
liver fibrosis and cirrhosis. To determine the predicting ability 
of APRI for hepatic fibrosis, an optimal cutoff value was set 
and sensitivity, specificity, positive predictive value (PPV), 
and ne  gative predictive value (NPV) were calculated (Table 3). 
Three people (34.8%) were in the group of APRI≤0.4669 and 15 
people (65.2%) were in the group with APRI>0.4669. The APRI 
value of meaningful fibrosis, when the cutoff value was set at 
0.4669, presented sensitivity of 94%, specificity of 66%, PPV 
of 94%, and NPV of 64%.
3. Relations between hepatic fibrosis and biopsy result using 
APRI
Table 4 shows compared values of APRI of the 6 NAFLD 
patients who were subjected to liver biopsy tests. For all 6 
pa  tients, the FibroScan values were over 8.1 kPa, which was 
above fibrosis stage one, and APRI value were the same or 
greater than 0.6531.
Discussion
Over the past few decades, the prevalence and incidence of 
obesity in children have increased significantly. Along with 
this increase, NAFLD has become the most common cause 
of chronic liver disease in children. Even though the natural 
history of child  hood NAFLD is uncertain, it is suggested 
that simple steatosis has a benign prognosis, while NASH 
Table 2. Multivariate analysis for factors associated with hepatic fibrosis in 
childhood nonalcoholic steatohepatitis
Variable
Hepatic fibrosis (stiffness>5.9 kPa)
OR (95% CI) P value
Triglyceride (mg/dL) 0.35 (0.18–0.70) 0.243
AST (IU/L) 2.97 (1.27–6.93) 0.045
ALT (IU/L) 0.69 (0.30–1.58) 0.069
Platelet count (10
3/μL) 2.80 (0.85–9.21) 0.051
APRI 3.68 (1.66–8.17) 0.035
Collagen IV (ng/dL) 0.96 (0.36­2.54) 0.067
OR, odds ratio; CI, confidence interval; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; APRI, AST to platelet ratio index. 
Table 3. Accuracy of APRI cutoff values in predicting significant hepatic fibrosis and cirrhosis 
APRI Total (n=23)
FibroScan
Sensitivity Specificity PPV NPV
Stiffness≤5.9 kPa Stiffness>5.9 kPa
≤0.4669 8 (34.8) 6 (85.7)   2 (12.5) 94 66 94 64
>0.4669 15 (65.2) 1 (14.3) 14 (87.5)
Values are presented as number (%).
APRI, aspartate aminotransferase to platelet ratio index; PPV, positive predictive value; NPV, negative predictive value.
Fig. 1. Receiver operating characteristics (ROC) curve for aspartate 
amino  transferase to platelet ratio index. The area under the ROC curves 
was 0.875 for the determination of hepatic fibrosis (stiffness>5.9 kPa).
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and fibrosis can develop into cryptogenic cirrhosis and 
hepatocellular carcinoma
1,2). Therefore, early identification 
of liver fibrosis in NAFLD can aid in prognosis and in de-
ter  mining a therapeutic plan, and it can prevent further de-
velopment of liver dis  ease
17,18). Evaluation of the progression 
of disease in NAFLD patients depends on serologic tests, 
US, computed tomography, MRI, and other radio  active test 
methods. However, fibrosis progression, especially in the early 
stage, is hard to predict and is often inaccurate. 
Until now, liver biopsy has been the best option for evalu-
ating liver fibrosis. It is the best and most objective method 
of testing, but it is also an invasive method which can bring 
about a pain and complications, especially in children. There-
fore, this method cannot be applied to all children. Also, if 
enough tissue is not provided, hepatic parenchyma cannot 
all be represented. In addition, a patient’s unwillingness to 
take the medication and the financial pressure make this 
method challenging for re  petitive medication and further 
investigation of the patient’s condition
17,18). Accordingly, 
research to find a nonin  vasive and accurate method has been 
increasing and new techniques are now being invented
19,20). 
Unfortunately, most of the newer methods are expensive or 
are complicated, and are, therefore, not appro  priate or con-
venient for common usage 
21,22). Also, chronic he  patitis C 
(CHC) patients were used in these investigations, and it is 
uncertain that they can be used childhood NAFLD patients. 
The recently developed FibroScan is a noninvasive method to 
measure the liver stiffness
14,23). FibroScan has some positive 
qualities, including a painless procedure, rapid test time (less 
than 5 minutes), and simple performance. It also covers and 
evaluates a larger part of the liver and is sensitive compared 
to the serological markers
2). LSM and fibrosis stage in NAFLD 
patients have a significant correlation, as confirmed by liver 
biopsy results
7). Also, LSM is feasible and related to liver 
fibrosis in children with chronic liver diseases
6). Therefore, 
LSM is a noninvasive and useful modality for identifying 
the severity of hepatic fibrosis in childhood NASH patients
7). 
FibroScan deter  mines the degree of liver fibrosis with high 
accuracy. However, the equipment is expensive and not 
practical for routine testing in most clinical unit worldwide
24). 
Liver tissue investigation would be much more convenient and 
financially supportable if a new and simple serologic liver 
fibrosis method were developed to replace liver biopsy and 
FibroScan. An ideal serologic fibrosis index which could apply 
and atypical organ such as liver, must have good repeatability, 
and low cost. Recently, several studies have attempted to use 
serologic tests to predict liver fibrosis and cirrhosis
25). Most 
childhood NASH patients that are asymptomatic and have a 
mild degree of elevated liver enzyme, such as AST and ALT, 
are followed up without any notifications of the significant 
hepatic fibrosis in medical practice. Therefore, it is important 
to introduce simple and predictive serological markers of 
hepatic fibrosis that can be used in children with NASH at any 
time. 
In this study, FibroScan was used to measure liver stiffness 
and to overcome the difficulty, limitations, and complications 
of liver biopsy in children as a baseline study of hepatic fibrosis. 
The simple and realistic method of APRI as a promising pre-
dictor was evaluated for usefulness in measuring liver fibro-
sis
8,26,27). Until now, many investigations have attempted to 
predict liver fibrosis and cirrhosis through serum markers. 
However, it is limited due to complex math equations
10). Com-
pared to this, APRI is based on two routine laboratory tests 
and is, therefore, a promising tool with limited expense and 
widespread availability
8). APRI has been used in the evaluation 
of patients with alcoholic liver fibrosis, CHB, and CHC with 
high accuracies
9). Although the study was performed for CHC, 
the high diagnostic power of APRI for predicting significant 
fibrosis has been reported
28). Also, relatively high accuracy of 
APRI for predicting significant fibrosis has been demonstrated 
even in children with CHB
29,30). However, there are few re-
ports using APRI as a noninvasive and useful method for the 
identification of hepatic fibrosis and cirrhosis in childhood 
NAFLD. Our study determined the useful  ness and reliability of 
the APRI in assessing fibrosis in children with NAFLD. Yoneda 
et al.
7) used FibroScan and set the liver stiffness cut  off value 
(kPa) to 5.9. They predicted sensitivity of 86.1%, spe  cificity of 
86.1%, PPV of 97.1%, and NPV of 59.3% (which was reasonably 
important). In this study, data from a previous investigation 
was used and FibroScan was used to mea  sure the liver flexi-
bility of NAFLD patient. Then, serologic tests were done to 
determine the correlation between AST and APRI. Based on 
the above cutoff value of 5.9, when fibrosis (≥F1) was predicted, 
it was shown that APRI had positive correlation [odds ratio, 
3.68; 95% confidence interval, 1.66 to 8.17; P=0.035] with he-
patic fibrosis (stiffness>5.9kPa). Commonly, because of the 
problems and limits of liver biopsies in predicting liver fibro  sis, 
Table 4. Findings Related to Assessment Methods of Hepatic Fibrosis in 6 
Liver Biopsy Cases 
Case Age (yr) Sex AST/ALT
(IU/L) Fibrosis stage FibroScan 
(kPa) APRI
1 13 M 225/372 2 18.7 2.1986
2 12 M 238/480 2 15.7 1.8288
3 10 M 131/326 2 11.8 1.3425
4 12 F 72/146 2   8.1 0.8371
5 11 M 90/140 2   8.2 0.7606
6 15 M 74/156 1   8.1 0.6531
AST, aspartate aminotransferase; ALT, alanine aminotransferase; APRI, AST to 
platelet ratio index; Fibrosis stage, fibrosis stage using liver biopsy.http://dx.doi.org/10.3345/kjp.2013.56.1.19
E Kim, et al. • Efficacy of APRI in childhood NASH
24
it is effective to use noninvasive serologic markers when area 
under the ROC (AUROC) values are over 0.80
17). AUROC values of 
APRI also considerably and accurately diagnosed liver fibrosis 
to those of 0.875. This conveyed superiority in diagnostic 
use  fulness. This did not differ significantly from AUROC 
val  ues targeted to CHC patients: 0.80, 0.81
25,31). This result 
sup  ported the validness of the recent study. In other studies, 
APRI has high relationship with liver fibrosis
9,26) and one re-
ported high diagnostic accuracy (AUROC, 0.88 [F>2]), 0.94 
[F=4])
28). Domestically, APRI had a better result as a serologic 
test indicating liver fibrosis than AAR for CHB patients
32). 
In this study, APRI predictability of fibrosis based on APRI 
cutoff value of 0.4669 were estimated according to ROC 
curve results. As a result, high predicted scores (sensi  tivity 
of 94%, specificity of 66%, PPV of 94%, and NPV of 64%) 
have shown that it could be used for predicting liver fibrosis. 
When 6 NAFLD patients, who have already done liver biopsy, 
were tested with FibroScan and APRI values, individual 
FibroScan values were the same or greater than 8.1 kPa, APRI 
values were the same or greater than 0.6531, and all the patients 
were above fibrosis stage 1. When an APRI cutoff of 0.4669 
was applied, it was applicable in finding out the existence 
of fibrosis. Therefore, APRI can be used to quickly predict 
liver fibrosis when liver biopsy is impossible to perform or 
inapplicable. Although there are several limitations, including 
the small number of patients and the short follow-up, APRI 
shows a possibility as a noninvasive method to assess hepatic 
fibrosis progression. Our results showed that APRI scores cor-
relate significantly to fibrosis in patients with NAFLD. In the 
future, if object patients increase and colossal cohort study 
operate and dia  gnostic accuracy on liver fibrosis is raised 
by combining serologic test and FibroScan, APRI could be a 
useful method for predicting liver fibrosis in the early stage, 
monitoring the process continuously, and determining a thera-
peutic cure. 
In conclusion, this study demonstrated that APRI could be 
an easy, noninvasive, simple, and readily available method 
for the prediction of significant hepatic fibrosis in childhood 
NAFLD. Follow-up evaluation for hepatic fibrosis should be 
performed by a pediatric hepatologist. 
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